Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : PYNG Technologies -- Ignore unavailable to you. Want to Upgrade?

To: Edward W. Richmond who wrote (3717)	4/28/1999 11:33:00 AM
From: LOR	Respond to of 8117

Hi Ed, Great post ...... I sincerely hope you are right and that we will all be able to celebrate PYNG's success in time for your 41'st wedding anniversary on August 2'nd but hasten to say that in this day and age reaching that worthy 41'st milestone will be far more of an accomplishment and reason for celebration then your PYNG "stock" investment. Strange as this may sound, even if we have to wait longer for PYNG I also think the odds are in favour of PYNG succeeding eventually. I think it is obvious from my posts that my frustrations have never been with the FAST-1 concept which I really like. For the benefit of those praying that PYNG succeeds in the very near future, heres hoping that far more is going on behind the scenes and that PYNG's share price rise significantly precedes "mass production". Best regards, LOR

To: Edward W. Richmond who wrote (3717)	4/30/1999 5:33:00 PM
From: Edward W. Richmond	Read Replies (1) \| Respond to of 8117

I received the following e-mail from Cambridge House International, sponsor of the Vancouver Technology Investment Forum. I assume it came to me because I attended the Forum. There doesn't seem to be news that is unknown to this forum. However, it is nice to see that information is being circulated among investors. BREAKING NEW GROUND IN EMERGENCY MEDICINE "Medical Breakthrough" in Intraosseous Infusion Pyng Medical Corp. (a subsidiary of Pyng Technologies Corp. listed on the OTC.BB. PYNGF and the Vancouver Stock Exchange Senior Listing PYT.V ) Vancouver, British Columbia, Canada has introduced a revolutionary new concept in Intraosseous Infusion for the Military, Emergency Room, and the Pre - Hospital market. The F.A.S.T 1‰ System (First Access for Shock and Trauma) provides medical emergency personnel the ability to achieve vascular access within 60 seconds each and every time when conventional methods such as I.V. are unavailable due to compromised veins from shock or trauma. The F.A.S.T 1 System was researched and developed with extensive input from military and civilian emergency caregivers in Canada and the USA and has received both FDA and Canadian Health Protection approval Problem Major trauma and blood loss, cardiac arrest, dehydration, deep shock, and other medical emergencies necessitate rapid, reliable access to a patient's blood stream to administer drugs and fluids. In the pre-hospital and emergency room environment, an infusion line placed in an arm vein is the standard route for obtaining this access. Throughout the North America over a million attempts to place intravenous (IV) lines fail every year. Paramedics who attend civilian emergencies often work in confusing and disrupted physical settings. Military personnel face the additional chaos of armed conflict and unpredictable factors of time and distance in the pre-hospital environment. In both civilian and military emergencies, the patient's compromised status frequently defeats the caregiver's attempts to gain rapid intravenous access. The Solution Pyng Medical Corp. provides the solution with the F.A.S.T 1‰ System for Adult Intraosseous Infusion, which has been approved by FDA and the Canadian Health Protection Branch. With the F.A.S.T 1 System, vascular access in adults can be reliably achieved in about one minute in pre-hospital, emergency room, and battlefield conditions. Intraosseous Infusion is a proven medical technique for getting drugs and fluids into the bloodstream. Resuscitative drugs and volume replacement fluids quickly flow from the bone marrow through numerous small blood vessels to enter the central vascular system. The F.A.S.T 1 System address emergency vascular access issues with the choice of Intraosseous Infusion to obtain vascular access, and the selection of a sternal insertion site for which the components of the F.A.S.T 1 System are specifically designed. Design features ensure easy identification of the site, quick and accurate penetration to the correct depth in the bone marrow space, resistance to strain and external forces, and immunity to interference with other procedures. The entire procedure takes less than 60 seconds inclusive of initial drug or fluid delivery. The F.A.S.T 1‰ System has completed International field trials. The FDA in the 1997 Annual Report selected the F.A.S.T 1 System as "a Significant Medical Breakthrough". The System has been fully evaluated by Walter Reed Army Research Institute. Pyng Medical Corp. staff has trained the Special Operations Command trainers at Ft. Bragg and the System is being used at the University of Uniformed Services. The F.A.S.T 1 System has been used in emergency hospitals and ambulance services in both Canada and the USA in a wide range of shock and trauma victims including cardiac arrest, diabetic hypoglycemic, endocarditis, severe trauma, hypovolemic and hypothermic shock. The System is in the process of being mass-produced for delivery in the fourth quarter of 1999. For further information contact Michael W. Jacobs, Pyng Medical Corp at Lab #534- 2660 Oak Street, Vancouver, B.C. V6H 3Z6 1(800) 349-7964 or visit our web site at pyng.com